G1 Therapeutics, Inc. announced the appointment of Andrew Perry as its Chief Commercial Officer. Mr. Perry replaces Soma Gupta who has left the Company for personal and professional reasons. He most recently served as Vice President, US Marketing at ViiV Healthcare NA, a joint venture majority-owned by GlaxoSmithKline. Mr. Perry brings nearly 25 years of leadership experience in product commercialization and managed markets to G1, having led multiple successful product launches and growing brands. He most recently served as Vice President, US Marketing at ViiV Healthcare NA, a joint venture majority-owned by GlaxoSmithKline. In this role, he was responsible for leading the marketing organization across HCP and patient channels to drive sales of the ViiV US portfolio, including oral and long-acting injectable products. There, he launched multiple products and managed two co-commercialization agreements. Prior to ViiV, Mr. Perry spent over 16 years at GlaxoSmithKline in positions of increasing responsibility, culminating in his tenure as Field Vice President, National Accounts, US Managed Markets & Government Affairs.